Open an Account
search icon
4
NOTIFICATIONS
Best Algo trading app in India
Bigul

NATCO PHARMA LTD. - 524816 - Closure of Trading Window

 Trading Window for dealing in the securities of the Company would remain closed for the Designated Persons, their immediate relatives and all connected persons covered in the Code of Conduct of the Company under the SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time with effect from Thursday, 1st April, 2021 to till 48 hours after the declaration of the Financial Results of the Company for the quarter and year ending on 31st March, 2021. The date of Board Meeting for declaration of the financial results of the Company for the Quarter and year ending 31st March, 2021 will be intimated in due course of time
31-03-2021
Bigul

Natco Pharma's board approves acquiring 1% in its Canadian subsidiary

 Drug major Natco Pharma on Friday said its board has approved acquiring about 1 per cent stake in its Canadian subsidiary
26-03-2021
Bigul

NATCO PHARMA LTD. - 524816 - Outcome Of Board Meeting

 To acquire 0.96% stake in NATCO Pharma (Canada) Inc., after this acquisition NATCO Pharma (Canada) Inc., become wholly owned subsidiary company of NATCO Pharma Ltd. Pursuant to NATCO Employee Stock Options Scheme 2017 (NATSOP2017) 37,000 Options were granted out of Lapsed Options of Face Value of Rs.2/- each
26-03-2021
Bigul

Streets remain cautiously positive on Natco Pharmas prospects

 In the near-term, Natco's prospects hinge on earnings growth in the pharma segment
16-03-2021
Bigul

NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 NATCO forays into Pheromone based technology for Integrated Pest Management
15-03-2021

Canadian company requests for licence to manufacture JJ's COVID-19 vaccine, may stir up patent war

 Biolyse has warned that if JJ denies licence, it can invoke a compulsory licensing provision in Canada to manufacture and export the vaccine. The Biolyse move may make other pharma companies in India and elsewhere to take notice. Though India has granted such a licence to Natco Pharma for Nexavar in 2012.
12-03-2021
Bigul

Natco's marketing partner gets USFDA nod for cancer drug

 The drug and its therapeutic equivalents had sales of $712 mn in the US during the 12 months ending December 2020
08-03-2021
Bigul

NATCO PHARMA LTD. - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 NATCO receives final approval for Everolimus tablets (generic for Afinitor(r)) for the US market
08-03-2021
Bigul

Natco Pharma Ltd - 524816 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

 NATCO receives final approval for Everolimus tablets (generic for Afinitor(r)) for the US market
08-03-2021
Bigul

Natco Pharma launches epilepsy drug

 Natco Pharma Limited has launched Brivaracetam tablets under brand Brecita in the domestic market. Brivaracetam is for the treatment of epilepsy. Briv
26-02-2021
Next Page
Close

Let's Open Free Demat Account